Breathing new life into rare respiratory disease treatment
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead product candidate, molgramostim inhalation solution (MOLBREEVI), is an inhaled recombinant GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease causing progressive respiratory failure.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountUnknown
Oct 2025
Jun 2024
Mar 2021
Jun 2017
Dec 2016
Mar 2013
Jun 2012
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.
